Nearly 60% of patients' skin symptoms are almost completely cleared!

Bristol-Myers Squibb (BMS) today announced two-year results from the POETYK PSO Long-Term Extension (LTE) trial, supporting the durable efficacy and consistent safety profile of deucravicitinib in adults with moderate-to-severe plaque psorias.

Psoriasis is a widespread chronic systemic immune-mediated disease and a serious global problem, affecting at least 100 million people worldwi.

Deucravicitinib is an oral, selective tyrosine kinase 2 (TYK2) allosteric inhibitor with a unique mechanism of acti.

▲ Deucravicitinib has a unique mechanism of action (Image source: Bristol-Myers Squibb official website)

The overall safety results observed for deucravicitinib are consistent with previously published results from the pivotal Phase 3 POETYK PSO-1 and POETYK PSO-2 clinical tria.

"At BMS, our cutting-edge research leads to novel, well-tolerated potential treatment options for patients affected by severe immune-mediated diseases such as psoriasis," said Jonathan Sadeh, PhD, Senior Vice President, Immunology and Fibrosis Development at B.

References

[1] New Two-Year Deucravacitinib Data Reinforce Durable Efficacy and Consistent Safety Profile in Treatment of Moderate to Severe Plaque Psorias.